MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
5.74
-0.09 (-1.54%)
Feb 11, 2026, 4:00 PM EST - Market closed
MannKind Revenue
MannKind had revenue of $82.13M in the quarter ending September 30, 2025, with 17.20% growth. This brings the company's revenue in the last twelve months to $313.79M, up 17.44% year-over-year. In the year 2024, MannKind had annual revenue of $285.50M with 43.50% growth.
Revenue (ttm)
$313.79M
Revenue Growth
+17.44%
P/S Ratio
5.46
Revenue / Employee
$770,975
Employees
407
Market Cap
1.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 285.50M | 86.54M | 43.50% |
| Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
| Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
| Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
| Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
| Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
| Dec 31, 2018 | 27.86M | 16.11M | 137.20% |
| Dec 31, 2017 | 11.75M | -163.01M | -93.28% |
| Dec 31, 2016 | 174.76M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 398.23M |
| Vericel | 258.72M |
| Stoke Therapeutics | 205.63M |
| Syndax Pharmaceuticals | 111.30M |
| Nurix Therapeutics | 83.98M |
| Tango Therapeutics | 66.50M |
MNKD News
- 2 days ago - MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) - GlobeNewsWire
- 6 days ago - 2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion - Seeking Alpha
- 16 days ago - MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - GlobeNewsWire
- 27 days ago - MoneyShow's Best Investment Ideas For 2026: Part 5 - Seeking Alpha
- 4 weeks ago - 6 stocks and ETFs that these unsung market heroes see outperforming in 2026 - Market Watch
- 4 weeks ago - MannKind Provides Business Updates and 2026 Growth Drivers - GlobeNewsWire
- 7 weeks ago - MannKind Shares FUROSCIX® Business Updates - GlobeNewsWire
- 2 months ago - MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients - Seeking Alpha